| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 08/02/2011 | CA2417984C Methods for treating autoimmune and chronic inflammatory conditions using antagonists of cd30 or cd30l |
| 08/02/2011 | CA2395593C Azaindoles |
| 08/02/2011 | CA2330829C Methods for treating a neurological disease by determining bche genotype |
| 07/29/2011 | CA2730634A1 Shunt delivery of curcumin |
| 07/28/2011 | WO2011091304A1 Delivery system for diagnostic and therapeutic agents |
| 07/28/2011 | WO2011091213A2 Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof |
| 07/28/2011 | WO2011091142A2 Crystalline and amorphous forms of olanzapine pamoate |
| 07/28/2011 | WO2011091050A1 Oligomer-tricyclic conjugates |
| 07/28/2011 | WO2011091033A1 Modulation of neurogenesis by ppar agents |
| 07/28/2011 | WO2011090911A1 Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| 07/28/2011 | WO2011090740A2 Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
| 07/28/2011 | WO2011090666A2 Methods for treating autism |
| 07/28/2011 | WO2011090317A2 Imidazopyrazinone derivatives with apoptosis inducing activity on cells |
| 07/28/2011 | WO2011090270A2 Composition containing osmotin for preventing and treating neurological disorders |
| 07/28/2011 | WO2011090065A1 Peptide vaccine |
| 07/28/2011 | WO2011090062A1 Piperazine compound having a pgds inhibitory effect |
| 07/28/2011 | WO2011089614A1 PROCESS FOR PREPARING ELETRIPTAN HYDROBROMIDE HAVING α-FORM |
| 07/28/2011 | WO2011089576A2 NOVEL COMPOSITIONS FOR REDUCING Aß 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) |
| 07/28/2011 | WO2011089416A1 Pyrazine derivatives |
| 07/28/2011 | WO2011089288A1 Composition comprising gdnf and tgf-β1 and use thereof for the treatment of a neurological disease |
| 07/28/2011 | WO2011089261A1 Use of hydrogels on the basis of guluronic acid- and/or mannuronic acid-containing polysaccharides for treating damage to the nervous system, promoting nerve growth, treating neurodegenerative diseases and cultivating neurons |
| 07/28/2011 | WO2011089168A2 Special composition for the use thereof as a drug |
| 07/28/2011 | WO2011089132A1 Nitrogen-containing heteroaryl derivatives |
| 07/28/2011 | WO2011088838A1 Novel 6,6a,7,8,9,10-hexahydro-4h-4,8,10a-triaza-acephenanthrylene derivatives as dopamine d2 ligands |
| 07/28/2011 | WO2011088836A1 NOVEL 4-(ARYL-4-SULFONYL)-6,6a,7,8,9,10-HEXAHYDRO-4H-4,8,10a-TRIAZA-ACEPHENANTHRYLENE AND 3-ARYLSULFONYL-6,6a,7,8,9,10-HEXAHYDRO-3H-3,8,10a-TRIAZA-CYCLOPENTA[C]FLUORENE DERIVATIVES AS SEROTONIN 5-HT6 LIGANDS |
| 07/28/2011 | WO2011088715A1 Use of albiflorin for anti-parkinson's disease |
| 07/28/2011 | WO2011088536A1 Use of at least one isoquinoline compound of formula i, pharmaceutical composition for treating or preventing neurodegenerative diseases and method for treating or preventing neurodegenerative diseases |
| 07/28/2011 | WO2011088525A1 A diagnostic test |
| 07/28/2011 | WO2011088504A1 Methods and compositions for improved nerve conduction velocity |
| 07/28/2011 | WO2011069075A3 Treating impulse control disorders with catechol-o- methyl-transferase inhibitors |
| 07/28/2011 | WO2011056037A9 Pharmaceutical composition containing, as active ingredients, lindera erythrocarpa extracts, fractions thereof, or compounds separated from the extracts |
| 07/28/2011 | WO2011038152A3 Toll-like receptor modulators and uses thereof |
| 07/28/2011 | WO2011035244A3 Tctex-1 regulatory sequence region as stem cell marker |
| 07/28/2011 | WO2011031327A3 Nicotine haptens, immunoconjugates and their uses |
| 07/28/2011 | WO2008089243A3 The redox/fyn/c-cbl pathway |
| 07/28/2011 | US20110185439 G protein coupled receptors and uses thereof |
| 07/28/2011 | US20110184220 Methods for the treatment of radiation or chemotherapy-induced tissue damage |
| 07/28/2011 | US20110184071 process for the preparation of amines |
| 07/28/2011 | US20110184069 Methods and compositions for administration of trpv1 agonists |
| 07/28/2011 | US20110184068 Use of (halobenzyloxy) benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium channel selective modulators |
| 07/28/2011 | US20110184067 O-desmethylvenlafaxine succinate polymorph & process for preparing thereof |
| 07/28/2011 | US20110184065 Use of spongosine for the treatment of pain |
| 07/28/2011 | US20110184063 Treatment of neurodegenerative conditions |
| 07/28/2011 | US20110184058 Synthesis of 6,7-dihydro-1h-indeno[5, 4-b] furan-8(2h)-one as intermediate in the preparation of remelteon |
| 07/28/2011 | US20110184057 Parenteral treatment with statins |
| 07/28/2011 | US20110184056 Use of statins as anticonvulsants, antiepileptics and neuroprotectors |
| 07/28/2011 | US20110184051 Pharmacological applications of mitochondrial dna assays |
| 07/28/2011 | US20110184046 Compositions And Methods For Inhibiting Expression Of GSK-3 Genes |
| 07/28/2011 | US20110184039 Pharmaceutical formulation |
| 07/28/2011 | US20110184038 Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| 07/28/2011 | US20110184037 Methods for treating an intervertebral disc using local analgesics |
| 07/28/2011 | US20110184034 Severe sepsis preventive therapeutic agent |
| 07/28/2011 | US20110184033 Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same |
| 07/28/2011 | US20110184031 G-Protein-Conjugated Receptor Agonist |
| 07/28/2011 | US20110184030 Pharmaceutically acceptable salt and polymorphic forms of flupirtine maleate |
| 07/28/2011 | US20110184026 C4-substituted alpha-keto oxazoles |
| 07/28/2011 | US20110184020 Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof For Treating Pain and Other Conditions |
| 07/28/2011 | US20110184018 Method for treating peripheral neuropathic pain |
| 07/28/2011 | US20110184015 Novel derivatives of pyrroloindole which are inhibitors of hsp90, compositions containing same, and use thereof |
| 07/28/2011 | US20110184014 New compounds |
| 07/28/2011 | US20110184008 Crystalline forms of an 8-azabicyclo[3.2.1]octane compound |
| 07/28/2011 | US20110184007 Pharmaceutical compositions configured to deter dosage form splitting |
| 07/28/2011 | US20110184000 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivates and their use as pde9a modulators |
| 07/28/2011 | US20110183997 Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors |
| 07/28/2011 | US20110183996 The 1-butyl-2-hydroxyaralkyl piperazine derivatives and the uses as anti-depression medicine thereof |
| 07/28/2011 | US20110183995 Eltoprazine for suppression of l-dopa induced dyskinesias |
| 07/28/2011 | US20110183994 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
| 07/28/2011 | US20110183993 Cycloalkane derivative |
| 07/28/2011 | US20110183992 Therapeutic agent for migraine |
| 07/28/2011 | US20110183991 5ht7 receptor ligands and compositions comprising the same |
| 07/28/2011 | US20110183985 Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors |
| 07/28/2011 | US20110183980 O-benzyl nicotinamide analogs as mglur5 positive allosteric modulators |
| 07/28/2011 | US20110183979 Nitrogen-containing heteroaryl derivatives |
| 07/28/2011 | US20110183977 Benzene, pyridine, and pyridazine derivatives |
| 07/28/2011 | US20110183976 5- and 6-membered heterocyclic compounds |
| 07/28/2011 | US20110183973 Novel Compounds |
| 07/28/2011 | US20110183971 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 07/28/2011 | US20110183967 Benzoxazole compounds and methods of use |
| 07/28/2011 | US20110183966 Aminopyridine kinase inhibitors |
| 07/28/2011 | US20110183963 Amino Acid Conjugates of Quetiapine, Process for Making and Using the Same |
| 07/28/2011 | US20110183961 Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof |
| 07/28/2011 | US20110183960 Thiophene-2-carboxamide derivatives, preparation thereof and therapeutic use thereof |
| 07/28/2011 | US20110183959 P38 kinase inhibiting agents |
| 07/28/2011 | US20110183957 Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| 07/28/2011 | US20110183955 2-Aminocarbonyl Substituted Piperazine or Diaza-Cyclic Compounds as Apoptosis Protein Inhibitors (Iap) Modulators |
| 07/28/2011 | US20110183948 Treatment of fibrotic conditions using hedgehog inhibitors |
| 07/28/2011 | US20110183947 Alpha-keto heterocycles as faah inhibitors |
| 07/28/2011 | US20110183946 Complexes Comprising alpha2-Adrenergic Receptor Agonists and Methods of Providing Neuroprotection or Treating or Inhibiting Progression of Glaucoma |
| 07/28/2011 | US20110183945 Long acting curcumin derivative, preparation method and pharmaceutical use thereof |
| 07/28/2011 | US20110183944 SUSTAINED-RELEASE NSAID/HMG CoA REDUCTASE INHIBITOR COMPOSITIONS |
| 07/28/2011 | US20110183942 Methods and Compositions for Treating Alzheimer's Disease |
| 07/28/2011 | US20110183922 Peptides that enhance acetylcholinesterase expression |
| 07/28/2011 | US20110183912 Agent for promoting neuronal differentiation and method therefor |
| 07/28/2011 | US20110183911 Method for improving neurotransmission failure using a novel agent |
| 07/28/2011 | US20110183909 Treatment of Mood and Anxiety Disorders |
| 07/28/2011 | US20110183903 USE OF PEGylated IGF-I VARIANTS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
| 07/28/2011 | US20110183889 Salicylanilide modified peptides for use as oral therapeutics |
| 07/28/2011 | US20110183886 Melanocortin receptor ligands |
| 07/28/2011 | US20110183884 Pan-antiviral peptides for protein kinase inhibition |
| 07/28/2011 | US20110183019 Methods of screening for and treating autism spectrum disorders and compositions for same |